Stallergenes announces FDA approval of Oralair®, the first sublingual immunotherapy tablet for the treatment of grass pollen allergy

ORALAIR® (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue...

Birch pollen sublingual immunotherapy solution demonstrated sustained efficacy and safety in adults with allergic rhino conjunctivitis over 2 pollen seasons

New positive clinical results from a phase III study, published in...


Follow us on :

STALLERGENES, a global allergy player


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. Stallergenes has a comprehensive approach of the allergic diseases with a complete portfolio combining diagnosis products and treatments and has brought the new generation of allergen immunotherapy treatments.




Approval of Oralair® in the USA


Stallergenes has been given on April, 1st 2014 the go-ahead from the U.S. Food and Drug Administration for Oralair®, its immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. Oralair® is the first sublingual immunotherapy tablet approved by the FDA. Greer®, a leader in the U.S. allergen immunotherapy market and partner of Stallergenes will lead the sales and marketing efforts for Oralair® in the United States